Solid Biosciences (SLDB) Liabilities and Shareholders Equity: 2017-2024
Historic Liabilities and Shareholders Equity for Solid Biosciences (SLDB) over the last 7 years, with Sep 2024 value amounting to $211.8 million.
- Solid Biosciences' Liabilities and Shareholders Equity rose 14.67% to $211.8 million in Q3 2024 from the same period last year, while for Sep 2024 it was $856.4 million, marking a year-over-year decrease of 2.60%. This contributed to the annual value of $164.9 million for FY2023, which is 36.62% down from last year.
- Latest data reveals that Solid Biosciences reported Liabilities and Shareholders Equity of $211.8 million as of Q3 2024, which was down 8.29% from $231.0 million recorded in Q2 2024.
- Solid Biosciences' 5-year Liabilities and Shareholders Equity high stood at $285.3 million for Q1 2021, and its period low was $40.5 million during Q3 2020.
- Moreover, its 3-year median value for Liabilities and Shareholders Equity was $208.5 million (2022), whereas its average is $212.4 million.
- Per our database at Business Quant, Solid Biosciences' Liabilities and Shareholders Equity tumbled by 69.05% in 2020 and then skyrocketed by 514.51% in 2021.
- Quarterly analysis of 5 years shows Solid Biosciences' Liabilities and Shareholders Equity stood at $171.2 million in 2020, then spiked by 35.76% to $232.4 million in 2021, then grew by 11.99% to $260.3 million in 2022, then tumbled by 36.62% to $164.9 million in 2023, then increased by 14.67% to $211.8 million in 2024.
- Its last three reported values are $211.8 million in Q3 2024, $231.0 million for Q2 2024, and $248.7 million during Q1 2024.